Sitagliptin Induces Tolerogenic Human Dendritic Cells

被引:1
|
作者
Drakul, Marija [1 ]
Tomic, Sergej [2 ]
Bekic, Marina [2 ]
Mihajlovic, Dusan [1 ]
Vasiljevic, Milos [1 ]
Rakocevic, Sara [1 ]
Dokic, Jelena [3 ]
Popovic, Nikola [3 ]
Bokonjic, Dejan [1 ]
Colic, Miodrag [1 ,4 ]
机构
[1] Univ East Sarajevo, Med Fac Foca, Foca 73300, Bosnia & Herceg
[2] Univ Belgrade, Inst Applicat Nucl Energy, Belgrade 11000, Serbia
[3] Univ Belgrade, Inst Mol Genet & Genet Engn, Belgrade 11000, Serbia
[4] Serbian Acad Arts & Sci, Belgrade 11000, Serbia
关键词
dipeptidyl peptidase 4 inhibitors; dendritic cells; tolerance; CD26; expression; regulatory T cells; NF-KAPPA-B; P38 MAPK INHIBITOR; PEPTIDASE; 4; DPP4; TH17; CELLS; T-CELLS; CD26; MATURATION; DIFFERENTIATION; TH2; ACTIVATION;
D O I
10.3390/ijms242316829
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sitagliptin, an anti-diabetic drug, is a dipeptidyl peptidase (DPP)-4/CD26 inhibitor with additional anti-inflammatory and immunomodulatory properties. In this study, we investigated for the first time the effect of sitagliptin on the differentiation and functions of human dendritic cells generated from monocytes (MoDCs) for 4 days using the standard GM-CSF/IL-4 procedure. LPS/IFN-gamma treatment for an additional 24 h was used for maturation induction of MoDCs. Sitagliptin was added at the highest non-cytotoxic concentration (500 mu g/mL) either at the beginning (sita 0d protocol) or after MoDC differentiation (sita 4d protocol). Sitagliptin impaired differentiation and maturation of MoDCs as judged with the lower expression of CD40, CD83, CD86, NLRP3, and HLA-DR, retention of CD14 expression, and inhibited production of IL-beta, IL-12p70, IL-23, and IL-27. In contrast, the expression of CD26, tolerogenic DC markers (ILT4 and IDO1), and production of immunoregulatory cytokines (IL-10 and TGF-beta) were increased. Generally, the sita 0d protocol was more efficient. Sitagliptin-treated MoDCs were poorer allostimulators of T-cells in MoDC/T-cell co-culture and inhibited Th1 and Th17 but augmented Th2 and Treg responses. Tolerogenic properties of sitagliptin-treated MoDCs were additionally confirmed by an increased frequency of CD4+CD25+CD127- FoxP3+ Tregs and Tr1 cells (CD4+IL-10+FoxP3-) in MoDC/T-cell co-culture. The differentiation of IL-10+ and TGF-beta+ Tregs depended on the sitagliptin protocol used. A Western blot analysis showed that sitagliptin inhibited p65 expression of NF-kB and p38MAPK during the maturation of MoDCs. In conclusion, sitagliptin induces differentiation of tolerogenic DCs, and the effect is important when considering sitagliptin for treating autoimmune diseases and allotransplant rejection.
引用
收藏
页数:24
相关论文
共 50 条
  • [41] Tolerogenic dendritic cells in organ transplantation
    Ochando, Jordi
    Ordikhani, Farideh
    Jordan, Stefan
    Boros, Peter
    Thomson, Angus W.
    TRANSPLANT INTERNATIONAL, 2020, 33 (02) : 113 - 127
  • [42] Thalidomide and Dexamethasone Combinatorial Treatment Induces Tolerogenic Signals by Systemic Immunomodulation of T Cells and Dendritic Cells
    Kim, B.
    Kim, E.
    Kim, J.
    Choi, H.
    Lee, H.
    Lee, J.
    Kim, M.
    Kim, Y.
    Huh, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 650 - 650
  • [43] Interferon-gamma induces tolerogenic dendritic cells with suppressive activity in experimental autoimmune encephalomyelitis
    Vilchez, Constanza
    Parra-Tello, Brian
    Gonzalez, Luis
    Prado, Carolina
    Pacheco, Rodrigo
    Naves, Rodrigo
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 1397 - 1397
  • [44] CTLA4-IG INDUCES TOLEROGENIC PROPERTIES OF DENDRITIC CELLS BY ALTERING CELLULAR METABOLISM
    Goutakoli, P.
    Papadaki, G.
    Papanikolaou, S.
    Vatsellas, G.
    Bertsias, G.
    Verginis, P.
    Sidiropoulos, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 8 - 8
  • [45] Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg
    Baur, Andreas S.
    Lutz, Manfred B.
    Schierer, Stephan
    Beltrame, Luca
    Theiner, Gabi
    Zinser, Elisabeth
    Ostalecki, Christian
    Heidkamp, Gordon
    Haendle, Ina
    Erdmann, Michael
    Wiesinger, Manuel
    Leisgang, Waltraud
    Gross, Stefanie
    Pommer, Ansgar J.
    Kaempgen, Eckhart
    Dudziak, Diana
    Steinkasserer, Alexander
    Cavalieri, Duccio
    Schuler-Thurner, Beatrice
    Schuler, Gerold
    BLOOD, 2013, 122 (13) : 2185 - 2194
  • [46] AMPK activation induces RALDH+ tolerogenic dendritic cells by rewiring glucose and lipid metabolism
    Brombacher, Eline C.
    Patente, Thiago A.
    van der Ham, Alwin J.
    Moll, Tijmen J. A.
    Otto, Frank
    Verheijen, Fenne W. M.
    Zaal, Esther A.
    de Ru, Arnoud H.
    Tjokrodirijo, Rayman T. N.
    Berkers, Celia R.
    van Veelen, Peter A.
    Guigas, Bruno
    Everts, Bart
    JOURNAL OF CELL BIOLOGY, 2024, 223 (10):
  • [47] CD40 signalling induces IL-10-producing, tolerogenic dendritic cells
    Tuettenberg, Andrea
    Fondel, Sabine
    Steinbrink, Kerstin
    Enk, Alexander H.
    Jonuleit, Helmut
    EXPERIMENTAL DERMATOLOGY, 2010, 19 (01) : 44 - 53
  • [48] Trophoblast cells induce a tolerogenic profile in dendritic cells
    Salamone, Gabriela
    Fraccaroli, Laura
    Gori, Soledad
    Grasso, Esteban
    Paparini, Daniel
    Geffner, Jorge
    Perez Leiros, Claudia
    Ramhorst, Rosanna
    HUMAN REPRODUCTION, 2012, 27 (09) : 2598 - 2606
  • [49] Protein Kinase C Inhibitor Generates Stable Human Tolerogenic Dendritic Cells
    Matsumoto, Takuya
    Hasegawa, Hitoshi
    Onishi, Sachiko
    Ishizaki, Jun
    Suemori, Koichiro
    Yasukawa, Masaki
    JOURNAL OF IMMUNOLOGY, 2013, 191 (05): : 2247 - 2257
  • [50] Clinical Tolerogenic Dendritic Cells: Exploring Therapeutic Impact on Human Autoimmune Disease
    Phillips, Brett Eugene
    Garciafigueroa, Yesica
    Trucco, Massimo
    Giannoukakis, Nick
    FRONTIERS IN IMMUNOLOGY, 2017, 8